Country comparison
CAR-T in China vs India
6 min read · Last verified: 2026-09-09
How CAR-T access works in India
India built its own CAR-T. NexCAR19 (actalycabtagene autoleucel), developed by ImmunoACT — an IIT Bombay spin-off working with Tata Memorial Centre — became India’s first approved CAR-T when the national regulator, the CDSCO, cleared it in October 2023. The approval rested on two trials in 64 patients with advanced B-cell lymphoma or leukaemia: 67% responded, and in about half the cancer disappeared entirely; 5% had severe cytokine release syndrome (NCI). Reported pricing runs around $50,000, with press reports of ₹30–42 lakh (roughly $36,000–50,000). ImmunoACT reported treating more than 350 patients across some 70 hospitals in its first full year.
A second homegrown product followed: Qartemi (varnimcabtagene autoleucel), approved in January 2025 for adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma, expected to cost around $60,000 per dose (AABB).
Two honest qualifications. Both approved products target CD19 — as of this verification there is no approved BCMA (myeloma) CAR-T in India; such options remain in trials. And the approvals are young: the published evidence base and long-term follow-up are smaller and shorter than for products marketed longer elsewhere. Payment is mostly out of pocket.
When patients compare India and China
Both are genuine lower-cost alternatives to Western list prices, but they are not interchangeable:
- Price favours India. NexCAR19 at around $50,000 is the lowest-priced approved CAR-T we could document anywhere.
- Product range favours China. China has six NMPA-approved products covering CD19 and BCMA targets — including commercial options for multiple myeloma, which India does not yet have.
- Scale and international flow favour China. Chinese high-volume centres treat more CAR-T patients and run established international departments; India’s commercial CAR-T experience, while growing fast, is younger and more domestically focused.
For an Indian patient whose disease fits a CD19 product, staying home is usually the obvious choice: the lowest price in the world, no visa, and follow-up in your own system. China enters the picture mainly when the needed target is not approved in India — myeloma being the clearest case — or when a specific centre’s experience matters for a complex case. A complete China journey totals $170,000–260,000, with product list prices of $140,000–180,000 (site dataset, NMPA list prices, verified 2026-07). See the itemized cost page.
The honest trade-offs
Price is not the whole bill. Wherever you go, ask for the total written quote and its exclusions — complications, bridging therapy, re-treatment. Younger approvals mean asking harder questions: how many patients with your exact diagnosis has this centre treated, where are its outcomes published, and what does its follow-up system look like at three, six, and twelve months?
For international patients choosing between the two destinations: an Indian journey can mean a long trip back for follow-up if you live elsewhere; a Chinese journey costs more but may offer the product your disease needs. Neither comparison is a recommendation — it only matters once a licensed treating team has said CAR-T is right for you, and which target it should aim at.
Questions to ask your treating team
- Is my disease covered by an approved product here, or only by a trial — or only abroad?
- How many patients like me has this centre treated, and where are the outcomes published?
- What is the all-in written quote, and what does it exclude?
- Who coordinates my follow-up, especially if I live in another city or country?
Where to go next
Sources
Compare with another country